U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07412197) titled 'Preventive Dendritic Cell Vaccination for Lynch Syndrome' on Feb. 05.
Brief Summary: The aim of this study is to assess safety, feasibility and immunogenicity of vaccination with neopeptide-loaded dendritic cells in Lynch Syndrome subjects who are known to be carrier of a germline MMR-gene mutation without signs of disease.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Lynch Syndrome
Intervention:
BIOLOGICAL: DC vaccination
Subjects in the DC vaccination arm will receive a maximum of 2 cycles each consisting of 3 DC injections intranodally (3-6x10^6 DC)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ra...